DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Online

The Value of Tokenizing Clinical Development Data for Real-World Evidence

概览

This On Demand Solution Provider Webinar is brought to you by DIA in cooperation with


merative


There is an increasing need to leverage real-world data to accelerate clinical development and reduce unnecessary spend. The true value of real-world data lies in the ability to link datasets for multiple use cases. Linkage between real-world datasets is possible without tokenization due to the patient-identifiable data points captured as part of health records and claims data. And though there are regulatory requirements that govern the handling of patient-identified data and the use cases thereafter, the likelihood of success in creating linked datasets is high. However, due to the need to preserve subject-level anonymity within the confines of regulated clinical research, tokenization of the clinical development data becomes key to enable the linkage of clinical development data with real-world data.

精选主题

  • The importance of establishing a linkable data infrastructure to help life science companies link clinical trial data and real-world data to their clinical trial any time
  • How the use of real-world data can enable pharmaceutical, medical device and research organizations to optimize and accelerate trial phases
  • Use cases of clinical development and real-world data

学习目标

At the conclusion of this webinar, participants should be able to:
  • Understand the current real-world data landscape for clinical development including Merative’s experience supporting customer use cases
  • Understand the benefits and approach of linking and leveraging clinical development data with real-world data
  • How tokenization supports the linkage of clinical development data to enable expanded real-world data use cases
  • How technology and trial design decisions impact the ability to tokenize and link clinical development data for real-world data related use cases

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。